Medtronic PLC

Medtronic PLC’s new brain‑computer interface partnership with Precision Neuroscience could boost neuromodulation profits by up to 20 % and drive AI‑enabled healthcare growth, offering a data‑driven solution for Parkinson’s and other neurological dis…

Medtronic PLC faces market volatility, a data‑breach inquiry, and shifting regulations—find out how these challenges impact investor confidence and future growth.

Medtronic’s StrataMR II shunt, with AI‑powered diagnostics, cuts revision rates, improves MRI safety, and supports real‑world evidence for smarter hydrocephalus care.

Medtronic’s Sphere‑9 catheter earns FDA breakthrough status, slashing time‑to‑market, boosting revenue by up to $80 M annually, and setting the stage for a 15 % market share growth in a $3.8 B cardiovascular device industry.

Medtronic’s Affera™ portfolio, highlighted by Sphere‑9’s breakthrough data and strategic acquisitions, promises faster approvals, higher success rates, and a stronger future in cardiac tech.

Medtronic PLC’s strategy in China, analyst shifts from buy to hold, and global investor interest reveal how the medical‑tech giant is navigating growth, margin pressure, and portfolio inclusion.

Medtronic’s FDA clearance of the OmniaSecure lead for left bundle branch pacing lifts shares slightly, boosting its conduction‑system portfolio and positioning the company ahead in the growing CRT‑LBB market.

Medtronic PLC unveils a CFO briefing and a strategic partnership with GE HealthCare to boost structural heart and minimally invasive device markets, promising growth and transparency for investors.

Medtronic’s MiniMed IPO targets $7 bn, with a $34 bn valuation, to expand diabetes tech and boost access while driving outcome‑based reimbursement.

Medtronic PLC’s Q3 earnings show 3.8% revenue growth, yet margin pressure prompts mixed analyst views. Discover how value‑based care, the Hugo system, and digital health investments shape the company’s long‑term prospects.